A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment. Fibroblast growth factor receptor (FGFR) gene alterations are frequent findings in various rare and advanced cancers refr...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar
Format:	Artigo
Idioma:	Inglês
Publicat:	Sciendo 2024-03-01
Col·lecció:	Acta Pharmaceutica
Matèries:	fgfr tyrosine kinase inhibitors fda approval erdafitinib infigratinib pemigatinib futibatinib
Accés en línia:	https://doi.org/10.2478/acph-2024-0005
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!